Transgenic models for prostate cancer research

Urologic Oncology

Volumn 2, Issue 4, 1996, Pages 119-122

  Greenberg, N M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0011156395     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(97)82844-X     Document Type: Article

References (52)

1. Berry SJ, Coffey DS, Ewing LL. A comparison of human and canine benign prostatic hyperplasia. In: Bruchovsky N, Chap-delaine A, Neumann F, (eds). Regulation of Androgen Action. Berlin: Congressduck, 1984; 59-68.
2. Pollard M. Spontaneous adenocarcinomas in aged germfree Wistar rats. J Natl Cancer Inst 1973;51:1235-41.
3. Shain SA, McCullough B, Segaloff A. Spontaneous adenocarcinomas of the ventral prostate of aged AXC rats. J Natl Cancer Inst 1975;55:177-80.
4. Adams JM, Cory S. Transgenic models of tumor development. Science 1991;254:1161-7.
5. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37:1927-33.
6. Pollard M, Luckert PH. Autochthonous prostate adenocarcinomas in Lobund-Wistar rats: A model system. Prostate 1987;11:219-27.
7. Pollard M, Luckert PH, Snyder L. The promotional effect of testosterone on induction of prostate-cancer in MNUsensitized L-W rats. Cancer Lett 1989;45:209-12.
8. Bosland MC, Prinsen MK, Dirksen TJM, Spit BJ. Characterization of adenocarcinoma of the dorsolateral prostate induced in wistar rats by N-methyl-N-nitrosourea, 7,12-dimethylbenz(a)anthracene, and 3,2'-dimethyl-4-aminobiphenyl, following sequential treatment with cyproterone acetate and testosterone proprionate. Cancer Res 1990;50:700-9.
9. Bosland MC, Prinsen MK. Induction of dorsolateral prostate adenocarcinoma and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-Nnitrosourea, 7,12-dimethylbenz(a)anthracene, and 3,2'-dimethyl-4-aminobiphenyl after sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res 1990;50:691-9.
10. Bogden AE, Taylor JE, Moreau JP, Coy DH. Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. Cancer Res 1990;50:2646-50.
11. Cooke DB, Quarmby VE, Mickey DD, Isaacs JT, French FS. Oncogene expression in prostate cancer: Dunning r3327 rat dorsal prostatic adenocarcinoma system. The Prostate 1988;13:263-72.
12. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, Yandell DW, Weichselbaum RR. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991;46:31-6.
13. van-Steenbrugge GJ, Schröder FH. Androgen-dependent human prostate cancer in nude mice. The PC-82 tumor model. Am J Clin Oncol 1988;2.
14. Chung LW, Li W, Cleave ME, et al. Human prostate cancer model: Roles of growth factors and extracellular matrices. J Cell Biochem 1992;(suppl.).
15. Thalman GN, Anezinis PE, Chang S-M, Zhau HE, Kim E, Hopwood VL, Pathak S, von Eschenbach AC, Chung LWK. Androgen-independent cancer progression and bone metastasis in the LnCaP model of human prostate cancer. Cancer Research 1994;54:2577-81.
16. Palmiter RD, Brinster RL. Transgenic mice. Cell 1985;41:343-5.
17. Palmiter RD, Brinster RL. Germ-line transformation of mice. Ann Rev Genetics 1986;20:465-99.
18. Hanahan D. Heritable formation of pancreatic -cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985:315:115-22.
19. Thompson TT, Southgate J, Kitchener G, and Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989:56:917-30.
20. Hurst HC, Parker MG. Rat prostatic steroid binding protein: DNA sequence and transcript maps of the two C3 gene. EMBO J 1983;2:769-74.
21. Harris SE, Parker MG, Webb P, Needham M, White R, Ham J, Harris MA. Mapping cis-DNA regulatory elements in seminal vesicle secretion genes, prostate C3(1) gene, and the mouse mammary tumor virus-long terminal repeat DNA. Prog Clin Biol Res 1988:284:53-76.
22. Harris SE, Harris MA, Johnson CM, Bean MF, Dodd JG, Matusik RJ, Carr SA, Crabb JW. Structural characterization of the rat seminal vesicle secretion II protein and gene. J Biol Chem 1990;265:9896-903.
23. Riegman PH, Vlietstra RJ, van dKJA, Romijn JC, Trapman J. Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene. Biochem Biophys Res Commun 1989;159:95-102.
24. Dodd JG, Sheppard PC, Marusik RJ. Characterization and cloning of highly abundant mRNAs of the rat dorsal prostate. J Biol Chem 1983:258:10731-7.
25. Matusik RJ, Cattini PA, Leco KJ, Sheppard PC, Nickel BE, Neubauer BI, Davie JR, Chang C, Liao S, Matuo Y, McKeehan WL. Regulation of gene expression in the prostate. In: Karr JP, (ed). Molecular and Cellular Biology of Prostate Cancer. New York: Plenum Press. 1991;299-314.
26. Matuo Y, Adams PS, Nishi N, Yasumitsu H, Crabb JW, Matusik RJ, McKeehan WL. The androgen-dependent rat prostate protein, probasin, is a heparin-binding protein that co-purifies with heparin-binding growth factor-1. In Vitro Cell Dev Biol 1989;25:581-4.
27. Allison J, Zhang Y-L, Parker MG. Tissue-specific and hormonal regulation of the gene for rat prostatic steroid-binding protein in transgenic mice. Mol Cell Biol 1989;9:2254-7.
28. Buttyan R, Slawin K. Rodent models for targeted oncogenesis of the prostate gland. Cancer and Metastasis Rev 1993;12:11-9.
29. Muller WJ, Lee FS, Dickson C, Peters G, Pattengale P, Leder P. The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J 1990;9:907-13.
30. Tutrone RFJ, Ball RA, Ornitz DM, Leder P, Richie JP. Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model. J Urol 1993:149:633-9.
31. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci (USA) 1995:92:3439-43.
32. Schaffner DL, Barrios R, Shaker M, Rajagopalan S, Huang S, Tindall DJ, Youn CYF, Overbeek PA, Lebovitz RM, Lieberman MW. Transgenic mice carrying a PSArasT24 hybrid gene develop salivary gland and GI tract neoplasms. Laboratory Investigation 1994;72:283-9.
33. Smith MS, Lechago J, Wines DR, MacDonald RJ, Hammer RE. Tissue-specific expression of kallikrein family transgenes in mice and rats. DNA Cell Biol 1992;11:345-58.
34. Frelinger J, Wei C, Willis R, Storozynsky E, Tilton B, Barth R, Lord E. Targeted CTL-mediated immunity for prostate cancer: Development of human PSA-expressing transgenic mice. (Abstract). Proc Am Assoc Can Res 1996;37:444.
35. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopolou R, Dodd JG, Duckworth ML, Rosen JM, Matusik RJ. The rat probasin gene promoter directs hormonally- and developmentally-regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8:230-9.
36. DeCaprio JA, Ludlow JW, Figge J, Skew J-Y, Huang C-M, Lee W-H, Marsilio E, Paucha E, Livingston DM. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988;17:275-83.
37. Linzer DH, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17:43-52.
38. Lane DP, Crawford LV. T-antigen is bound to host proteins in SV-40 transformed cells. Nature 1979;278:261-3.
39. Yang G, Stapleton A, Wheeler TM, Truong LD, Timme TL, Scardino PT, Thompson TC. Clustered p53 immunostaining-a novel pattern associated with prostate cancer progression. Clinical Cancer Research 1996:2:399-401.
40. Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K, Danenberg PV. Tumor suppressor gene p53 mutations in human prostate cancer. The Prostate 1995;27:18-24.
41. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, Voneschenbach AC, Conti CJ, Chung L. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 1995:45:470-5.
42. Eastham JA, Stapleton A, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Association of p53 mutations with metastatic prostate cancer. Clinical Cancer Research 1995;l:llll-8.
43. Bauer JJ, Sesterhenn IA, Mostofi KF, Mcleod DG, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clinical Cancer Research 1995:1:1295-300.
44. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM. Molecular biology of prostate cancer. Semin Oncol 1994:21:514-21.
45. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, Srivastava S. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995:154:414-21.
46. Konishi N, Hiasa Y, Tsuzuki T, Matsuda H, Tao M, Nakamura M, Naito H, Kitahori Y, Shiraishi T, Yatani R, Shimazaki J, Lin JC. Detection of rb,pl6/cdkn2 and p15(ink4b) gene alterations with immunohistochemical studies in human prostate carcinomas. Int J Oncol 1996:8:107-12.
47. Ittmann MM, Wieczorek R. Alterations of the retinoblastoma gene in clinically localized, stage b prostate adenocarcinomas. Human Pathology 1996;27:28-34.
48. Sarkar FH, Sakr W, Li YW, Macoska J, Ball DE, Crissman JD. Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas. The Prostate 1992;21:145-52.
49. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994;91:11236-40.
50. Jorcyk CL, Liu M-L, Maroulakou JG, Shibata M-A, Resau JH, Green JE. Transgenic mouse prostate and mammary adenocarcinoma cell lines: Reagents for cancer vaccines. (Abstract). Proc Am Assoc Can Res 1996;37:444.
51. Morton RAJ, Gingrich JR, Foster BA, Madewell L, Greenberg NM. E-cadherin expression in a transgenic animal model of metastatic prostate cancer. Urology 1996;155:514A.
52. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, and Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996:56:4096-4102.